Inventor
EPSTEIN ALAN L
US30 patents
⚠️ This page may combine multiple inventors who share the name “EPSTEIN ALAN L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV SOUTHERN CALIFORNIA
13 patentsUS7371371B2May 13, 2008
Interleukin-2 mutants with reduced toxicity
UNIV SOUTHERN CALIFORNIA59 citations97
US7514073B2Apr 7, 2009
Therapeutic use of interleukin-2 mutants
UNIV SOUTHERN CALIFORNIA49 citations95
US7803361B2Sep 28, 2010
Therapeutic use of interleukin-2 mutants
UNIV SOUTHERN CALIFORNIA31 citations92
US6008319ADec 28, 1999
Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
UNIV SOUTHERN CALIFORNIA29 citations92
US6007817ADec 28, 1999
Vasopermeability enhancing immunoconjugates
UNIV SOUTHERN CALIFORNIA19 citations90
US11667715B2Jun 6, 2023
Lym-1 and Lym-2 antibody compositions and improved car constructs
UNIV SOUTHERN CALIFORNIA0 citations62
US6403096B1Jun 11, 2002
Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
UNIV SOUTHERN CALIFORNIA1 citations62
US6524823B2Feb 25, 2003
Vasopermeability-enhancing conjugates
UNIV SOUTHERN CALIFORNIA2 citations60
US6274343B1Aug 14, 2001
Vasopermeability enhancing immunoconjugates
UNIV SOUTHERN CALIFORNIA2 citations60
US11136401B2Oct 5, 2021
Car t-cell therapy directed to LHR for the treatment of solid tumors
UNIV SOUTHERN CALIFORNIA1 citations56
US10961317B2Mar 30, 2021
CD20 scFv-ELPs methods and therapeutics
UNIV SOUTHERN CALIFORNIA0 citations56
US6737064B2May 18, 2004
Method for the diagnosis of neoplastic tissue comprising administering a vasopermeability enhancing peptide of human interleukin-2
UNIV SOUTHERN CALIFORNIA0 citations51
US6696276B2Feb 24, 2004
Vasopermeability-enhancing conjugates
UNIV SOUTHERN CALIFORNIA0 citations49
EPSTEIN ALAN L
8 patentsUS8124066B2Feb 28, 2012
Methods of using interleukin-2 mutants with reduced toxicity
EPSTEIN ALAN L37 citations95
US9522958B2Dec 20, 2016
Cancer targeted innate immunity
EPSTEIN ALAN L34 citations93
US10196435B2Feb 5, 2019
OX40L fusion protein for the immunotherapy of tumors of veterinary animals
EPSTEIN ALAN L2 citations70
US8883497B2Nov 11, 2014
Human myeloid derived suppressor cell cancer markers
EPSTEIN ALAN L4 citations67
US10711064B2Jul 14, 2020
Lym-1 and Lym-2 targeted CAR cell immunotherapy
EPSTEIN ALAN L1 citations62
US8795672B2Aug 5, 2014
Compositions and methods for cancer immunotherapy
EPSTEIN ALAN L2 citations62
US8545838B2Oct 1, 2013
Compositions and methods for cancer immunotherapy
EPSTEIN ALAN L3 citations62
US9746480B2Aug 29, 2017
Human myeloid derived suppressor cell cancer markers
EPSTEIN ALAN L0 citations46
TECHNICLONE INC
4 patentsUS5194594AMar 16, 1993
Modified antibodies
TECHNICLONE INC181 citations97
US6071491AJun 6, 2000
Detection of necrotic malignant tissue and associated therapy
TECHNICLONE INC33 citations95
US6017514AJan 25, 2000
Detection of necrotic malignant tissue and associated therapy
TECHNICLONE INC71 citations95
US5990286ANov 23, 1999
Antibodies with reduced net positive charge
TECHNICLONE INC79 citations95
CANCER BIOLOG INC
3 patentsUS5019368AMay 28, 1991
Detection of necrotic malignant tissue and associated therapy
CANCER BIOLOG INC174 citations98
US4861581AAug 29, 1989
Detection of necrotic malignant tissue and associated therapy
CANCER BIOLOG INC194 citations98
US5882626AMar 16, 1999
Detection of necrotic malignant tissue and associated therapy
CANCER BIOLOG INC35 citations95